4539
NIPPON CHEMIPHAR CO.,LTD.
日本ケミファ
- Industry
- Pharmaceutical
- Market
- Standard
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
31,541
Mar 2022
32,506
Mar 2023
31,559
Mar 2024
30,748
Mar 2025
32,570
Operating profit(million JPY)
Mar 2021
564
Mar 2022
825
Mar 2023
-241
Mar 2024
-494
Mar 2025
606
Operating profit margin(%)
Mar 2021
1.79
Mar 2022
2.54
Mar 2023
-0.76
Mar 2024
-1.61
Mar 2025
1.86
Profit before tax(million JPY)
Mar 2021
713
Mar 2022
976
Mar 2023
480
Mar 2024
-202
Mar 2025
253
Profit(million JPY)
Mar 2021
495
Mar 2022
700
Mar 2023
339
Mar 2024
-180
Mar 2025
294
Total assets(million JPY)
Mar 2021
47,124
Mar 2022
49,453
Mar 2023
48,571
Mar 2024
49,548
Mar 2025
49,851
Cash and cash equivalents(million JPY)
Mar 2021
10,505
Mar 2022
11,645
Mar 2023
10,529
Mar 2024
9,200
Mar 2025
7,021
Cash flows from operating activities(million JPY)
Mar 2021
1,503
Mar 2022
1,801
Mar 2023
-916
Mar 2024
296
Mar 2025
-265
Cash flows from investing activities(million JPY)
Mar 2021
-1,024
Mar 2022
35
Mar 2023
-394
Mar 2024
-3,139
Mar 2025
-1,655
Cash flows from financing activities(million JPY)
Mar 2021
29
Mar 2022
-793
Mar 2023
144
Mar 2024
1,447
Mar 2025
-305
Return on equity(%)
Mar 2021
2.8
Mar 2022
3.8
Mar 2023
1.8
Mar 2024
-1
Mar 2025
1.6
Equity ratio(%)
Mar 2021
38.2
Mar 2022
37.4
Mar 2023
38.1
Mar 2024
37.3
Mar 2025
38.4
Earnings per share(JPY per share)
Mar 2021
137.75
Mar 2022
194.33
Mar 2023
94.07
Mar 2024
-50.14
Mar 2025
81.72
Net assets per share(JPY per share)
Mar 2021
5,006.49
Mar 2022
5,119.99
Mar 2023
5,130.65
Mar 2024
5,116.02
Mar 2025
5,312.46
Dividend per share(JPY per share)
Mar 2021
50
Mar 2022
50
Mar 2023
50
Mar 2024
50
Mar 2025
50
Payout ratio(%)
Mar 2021
36.3
Mar 2022
25.73
Mar 2023
53.15
Mar 2024
-
Mar 2025
61.18
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.